Harpoon Therapeutics (HARP)

Recent Quarterly Results

Source: Company filings

Price Chart

Harpoon Therapeutics (HARP) stock price: $23.00 (+0.02, +0.09%)

Why Bull

• •Harpoon's recent insider buying suggests those in the know see long-term value, similar to when insiders loaded up on Apple before major product launches. The social buzz around their novel cancer therapies is growing, indicating increased investor interest. Bullish community chatter highlights the potential of their TriTAC platform, a sentiment reminiscent of early enthusiasm for CRISPR technology. Market perception seems to be shifting positively as Harpoon presents at key industry conferences, potentially signaling future partnerships.
• •Harpoon's recent insider buying suggests those in the know see long-term value, similar to when insiders loaded up on Apple before major product launches.
• •The social buzz around their novel cancer therapies is growing, indicating increased investor interest.
• •Bullish community chatter highlights the potential of their TriTAC platform, a sentiment reminiscent of early enthusiasm for CRISPR technology.

Why Bear

• •Despite the hype, clinical trial outcomes are always uncertain, and Harpoon is no exception; remember the initial excitement around certain Alzheimer's drugs that ultimately disappointed. Community sentiment also reveals concerns about competition in the immunotherapy space, a crowded field akin to the electric vehicle market. Some investors are wary of Harpoon's cash burn rate, drawing parallels to biotech firms that struggled to secure funding during the 2008 financial crisis. Market perception could quickly sour if upcoming data doesn't meet expectations, a risk amplified in the volatile biotech sector.
• •Despite the hype, clinical trial outcomes are always uncertain, and Harpoon is no exception; remember the initial excitement around certain Alzheimer's drugs that ultimately disappointed.
• •Community sentiment also reveals concerns about competition in the immunotherapy space, a crowded field akin to the electric vehicle market.
• •Some investors are wary of Harpoon's cash burn rate, drawing parallels to biotech firms that struggled to secure funding during the 2008 financial crisis.

• US GDP growth falls sharply to 1.4% rate in fourth quarter
  International homepage · Feb 20, 2026
• Morgan Stanley issues sharp take on the stock market
  TheStreet · Feb 20, 2026

Rationale

AI-generated technical analysis for HARP including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Set your price target for Harpoon Therapeutics (HARP), choose a timeframe, and track your prediction accuracy.

Current price: $23.00

No insider trades in the last 30 days.

Score Factors

• Revenue Growth 6/100

  Revenue increased 34.9% YoY, reflecting moderate but steady business growth.

• Gross Margin 10/100

  Gross margin of 90.3% shows excellent pricing power and a strong competitive moat.

• Operating Leverage 6/100

  Revenue growth is driving operating leverage, meaning profits can grow faster than costs.

• Cash Runway 6/100

  Adequate cash of $52M covers near-term needs but may require additional funding for aggressive expansion.

• R&D Intensity 10/100

  Investing 255.0% of revenue in R&D signals heavy commitment to innovation and future product pipeline.

• Insider Activity 6/100

  No significant insider buying or selling recently, which is neutral for the stock outlook.

• Short Interest 5/100

  Float and volume data unavailable for liquidity analysis.

• Price Momentum 0/100

  No bullish technical signals detected. The stock lacks upward price momentum currently.

• News Sentiment 5/100

  No sentiment data available

What does this score mean?

The MoonshotScore rates HARP's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

What does Harpoon Therapeutics, Inc. do?

Harpoon Therapeutics is a clinical-stage biotechnology company focused on developing novel cancer immunotherapies based on its proprietary TriTAC platform. The TriTAC platform engineers T cells to target and destroy cancer cells, offering a potentially more effective and less toxic alternative to traditional cancer treatments. The company's pipeline includes product candidates targeting various cancers, including small cell lung cancer, multiple myeloma, and ovarian/pancreatic cancer. Harpoon's goal is to develop and commercialize innovative immunotherapies that improve outcomes for patients with cancer.

Is HARP stock a good buy?

HARP stock presents a high-risk, high-reward investment opportunity. The company's innovative TriTAC platform and promising clinical pipeline offer significant potential for growth. However, as a clinical-stage company, Harpoon faces significant risks related to clinical trial outcomes and regulatory approvals. The company's negative profit margin (-210.4%) and reliance on future funding are also important considerations. Investors should carefully weigh the potential upside against the inherent risks before investing in HARP stock. Positive clinical trial data could significantly increase the stock price, while negative data could have the opposite effect.

What are the main risks for HARP?

The main risks for Harpoon Therapeutics include clinical trial failures, competition from other immunotherapy companies, regulatory hurdles, and financial risks. Clinical trial failures could significantly impact the company's value and delay or prevent product approvals. Competition from larger pharmaceutical companies with more resources could limit Harpoon's market share. Regulatory delays or rejections could also delay or prevent product approvals. The company's high cash burn rate and reliance on future funding pose financial risks. Additionally, patent challenges and intellectual property disputes could threaten the company's competitive advantage.

Is HARP a good stock to buy?

Whether HARP is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the HARP MoonshotScore?

The MoonshotScore for HARP is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is HARP data updated?

HARP stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to HARP is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for HARP?

Growth catalysts for Harpoon Therapeutics (HARP) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Harpoon Therapeutics's specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are HARP's main competitors?

Harpoon Therapeutics (HARP) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether HARP has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about HARP?

Wall Street analyst coverage for HARP includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is HARP's market cap?

Market capitalization (market cap) for HARP is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows HARP's current market cap alongside enterprise value and other valuation metrics.

How has HARP stock performed recently?

HARP's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing HARP's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in HARP?

Key risk categories for HARP include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures HARP's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling HARP?

Insider trading activity for HARP tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is HARP a good stock for beginners?

Harpoon Therapeutics (HARP) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is HARP for first-time investors?

Every stock carries risk, including Harpoon Therapeutics (HARP). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like HARP.